AKT and MET Signalling Mediates Antiapoptotic Radioresistance in Head Neck Cancer Cell Lines
Overview
Authors
Affiliations
Objectives: Induction of apoptosis is a major mechanism of radiosensitivity in different types of cancer. In contrast, EGFR/PI3K/AKT signalling and recently the presence of so-called cancer stem cells are discussed as reasons for radioresistance.
Materials And Methods: The study investigates mechanisms of apoptosis, key oncogenes of the PI3K/AKT pathway and the presence of cancer cells with stem cell properties during irradiation in two cell lines (PCI-9A, and PCI-15) of head and neck squamous cell carcinoma. WST-1-tests, qRT-PCR, western blots and FACS analysis were performed for analysis.
Results: The two cell lines presented different degrees of cell death upon irradiation. The radiosensitive cell line PCI-9A showed increased apoptosis after irradiation measured by expressed cleaved caspases 3 and 7 while the radioresistant cell line PCI-15 upregulated antiapoptotic Survivin and BCL2A1 mRNA. Besides, increased PI3K/AKT- and ERK1/2-signalling was associated with radioresistance accompanied by loss of PTEN function through phosphorylation on S380. Blockade of pAKT increased radiation-induced cell death, and moreover, led to an upregulation of pMET in the radioresistant cell line. The percentage of ALDH-positive tumour cells was markedly decreased after irradiation in the radiosensitive cell line.
Conclusions: Functional apoptosis is mandatory for sensitivity to irradiation in head neck cancer cells. Upregulation of the AKT-pathway seems to be one reason for poor radioresponse. Activated MET may also predict radioresistance, possibly through ERK1/2 signalling. Moreover MET may indicate the presence of cancer stem cells facilitating radioresistance as shown by increased ALDH expression.
Kawano M, Tanaka K, Itonaga I, Iwasaki T, Kubota Y, Tsumura H Oncol Res. 2023; 31(5):631-643.
PMID: 37547755 PMC: 10398415. DOI: 10.32604/or.2023.029745.
Targeting AKT/mTOR in Oral Cancer: Mechanisms and Advances in Clinical Trials.
Harsha C, Banik K, Ang H, Girisa S, Vikkurthi R, Parama D Int J Mol Sci. 2020; 21(9).
PMID: 32384682 PMC: 7246494. DOI: 10.3390/ijms21093285.
Lang L, Lam T, Chen A, Jensen C, Duncan L, Kong F Cells. 2020; 9(3).
PMID: 32106632 PMC: 7140405. DOI: 10.3390/cells9030533.
Riva G, Pecorari G, Biolatti M, Pautasso S, Lo Cigno I, Garzaro M Mol Biol Rep. 2019; 46(3):3333-3347.
PMID: 30980272 DOI: 10.1007/s11033-019-04795-7.
The Role of PI3K in Met Driven Cancer: A Recap.
Hervieu A, Kermorgant S Front Mol Biosci. 2018; 5:86.
PMID: 30406111 PMC: 6207648. DOI: 10.3389/fmolb.2018.00086.